Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:137608Q87.3
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (SOLAMEN syndrome) is an extremely rare mosaic overgrowth disorder characterized by the combination of segmental (localized) body overgrowth, lipomatosis (abnormal fatty tissue growths), arteriovenous malformations (abnormal connections between arteries and veins), and epidermal nevi (benign skin growths). This condition is considered a segmental manifestation of Cowden syndrome (PTEN hamartoma tumor syndrome) caused by postzygotic (somatic) mosaic mutations in the PTEN gene, which is a tumor suppressor gene. The disorder affects multiple body systems including the skin, soft tissues, vasculature, and skeletal system. Clinical features typically present at birth or during early childhood and may include asymmetric or segmental overgrowth of a limb or body region, multiple lipomas, vascular malformations (particularly arteriovenous malformations), and epidermal nevi following a pattern along the lines of Blaschko. Patients may also develop features overlapping with Cowden syndrome, including an increased risk for certain tumors, particularly if a germline PTEN mutation coexists with the somatic mutation (a phenomenon known as type 2 segmental mosaicism). Macrocephaly and other hamartomatous growths may also be observed. There is no curative treatment for SOLAMEN syndrome. Management is multidisciplinary and symptom-based, involving dermatologists, vascular specialists, orthopedic surgeons, and oncologists. Treatment may include surgical removal of lipomas or epidermal nevi, embolization or other interventional procedures for arteriovenous malformations, and enhanced cancer surveillance given the association with PTEN mutations. Emerging therapies targeting the PI3K/AKT/mTOR pathway, which is dysregulated due to PTEN loss, are being investigated in related overgrowth syndromes and may hold future promise.

Also known as:

Clinical phenotype terms— hover any for plain English:

Venous insufficiencyHP:0005293Excessive wrinkled skinHP:0007392HamartomaHP:0010566Neoplasm of the breastHP:0100013Arteriovenous malformationHP:0100026Neoplasm of the thyroid glandHP:0100031Upper limb asymmetryHP:0100560Ovarian neoplasmHP:0100615Visceral angiomatosisHP:0100761LymphangiomaHP:0100764
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.

View clinical trials →

No actively recruiting trials found for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome community →

No specialists are currently listed for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndromeForum →

No community posts yet. Be the first to share your experience with Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.

Start the conversation →

Latest news about Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome

No recent news articles for Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome

What is Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome?

Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome (SOLAMEN syndrome) is an extremely rare mosaic overgrowth disorder characterized by the combination of segmental (localized) body overgrowth, lipomatosis (abnormal fatty tissue growths), arteriovenous malformations (abnormal connections between arteries and veins), and epidermal nevi (benign skin growths). This condition is considered a segmental manifestation of Cowden syndrome (PTEN hamartoma tumor syndrome) caused by postzygotic (somatic) mosaic mutations in the PTEN gene, which is a tumor suppressor gene. T

How is Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome inherited?

Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome typically begin?

Typical onset of Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome is neonatal. Age of onset can vary across affected individuals.